Citadel Advisors
LSTA icon

Citadel Advisors’s Lisata Therapeutics LSTA Stock Holding History

Citadel Advisors’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$114K Buy
+22,666
New +$93.6K ﹤0.01% 11900
2025
Q1 		– Sell
-23,273
Closed -$69.4K – 15129
2024
Q4 		$69.4K Buy
+23,273
New +$66.6K ﹤0.01% 11984
2024
Q1 		– Sell
-14,131
Closed -$38.6K – 15107
2023
Q4 		$38.6K Sell
14,131
-4,451
-24% -$10.5K ﹤0.01% 12043
2023
Q3 		$38.8K Buy
18,582
+1,404
+8% +$3.9K ﹤0.01% 12030
2023
Q2 		$63.6K Buy
+17,178
New +$62.5K ﹤0.01% 11518
2023
Q1 		– Sell
-10,082
Closed -$25.1K – 15159
2022
Q4 		$25.1K Buy
+10,082
New +$37K ﹤0.01% 12938
2022
Q2 		– Sell
-1,203
Closed -$9.9K – 13595
2022
Q1 		$13K Buy
+1,203
New +$13.8K ﹤0.01% 13344
2021
Q4 		– Sell
-4,947
Closed -$76.4K – 14350
2021
Q3 		$91K Buy
+4,947
New +$97K ﹤0.01% 12966
2021
Q2 		– Sell
-2,881
Closed -$68.3K – 14084
2021
Q1 		$83K Sell
2,881
-2,299
-44% -$69.7K ﹤0.01% 12615
2020
Q4 		$111K Buy
5,180
+1,409
+37% +$33.4K ﹤0.01% 10157
2020
Q3 		$102K Buy
+3,771
New +$119K ﹤0.01% 9265
2017
Q1 		– Sell
-1,052
Closed -$45K – 7789
2016
Q4 		$45K Buy
+1,052
New +$60.4K ﹤0.01% 6892
2016
Q3 		– Sell
-72
Closed -$6K – 7522
2016
Q2 		$6K Sell
72
-133
-65% -$12.2K ﹤0.01% 6747
2016
Q1 		$23K Buy
+205
New +$20.1K ﹤0.01% 6433
2015
Q3 		– Sell
-15
Closed -$4K – 9080
2015
Q2 		$4K Buy
+15
New +$5.57K ﹤0.01% 8564
2015
Q1 		– Sell
-227
Closed -$123K – 8704
2014
Q4 		$128K Buy
227
+172
+313% +$117K ﹤0.01% 6424
2014
Q3 		$45K Buy
+55
New +$48.1K ﹤0.01% 6960
2014
Q2 		– Sell
-89
Closed -$86.5K – 8146
2014
Q1 		$94K Buy
+89
New +$96.5K ﹤0.01% 6258

Other funds holding LSTA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citadel Advisors's LSTA Position: Q1 2026 in Review

Citadel Advisors opened a new position in Lisata Therapeutics (LSTA) in Q1 2026: 22,666 shares worth $114K. The stake represents ﹤0.01% of the portfolio and ranks #11900 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in LSTA as recently as Q4 2024.

Citadel Advisors first reported a position in LSTA in Q1 2014 and has held it in 18 quarters since. The position peaked at $128K in Q4 2014. 34 funds tracked by Wall St. Rank hold LSTA as of Q1 2026.

  • Citadel Advisors held 22,666 shares of Lisata Therapeutics worth $114K as of Q1 2026.
  • Lisata Therapeutics was a new Citadel Advisors position in Q1 2026.
  • Lisata Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11900 holding.
  • Citadel Advisors first reported a position in Lisata Therapeutics in Q1 2014 and has held it in 18 quarters since.
  • Citadel Advisors's Lisata Therapeutics position peaked at $128K in Q4 2014.
  • 34 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.